Trial: 201911012

A Single-Arm, Open-Label, Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease after Peripheral Blood Hematopoietic Cell Transplantation



Principal Investigator

Schroeder, Mark

Disease Site

Hodgkin Lymphoma; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic

Learn more about this study at: